Matrix metalloproteinase-9 is a protease enzyme that plays a role in tissue destruction, tissue remodelling, and inflammation and is a proteinase studied in human PGD. Protein MMP-9 concentration and activity are increased in the urine of T2DM patients, most common in patients with albuminuria, and correlate with kidney injury. This study aims to determine and compare the MMP-9 levels in urine in diabetic and non-diabetic nephropathy subjects. The study design was cross-sectional with a total sample of 52 samples; there were 26 samples from diabetic nephropathy and 26 from non-diabetic nephropathy. MMP-9 urine levels were examined using the ELISA (Assay Genie, Irelaind) method. The results showed that there was a significant difference between urinary MMP-9 in diabetic nephropathy compared to DM without nephropathy (14.04 ng/mL and 3.07 ng/mL). Correlation test results of urine MMP-9 and urine albumin were r =0.53, p<0.001 (p≤0.05), and the AUC value obtained from the ROC method is 83.1%(95% CI 71.5% - 94.7%), p = <0.001 from a cut-off value of 3.96 ng/mL with a sensitivity and specificity value of 76.9% in diagnosing diabetic nephropathy. The conclusion is that urine MMP-9 levels are higher in diabetic nephropathy subjects than DM without nephropathy; there is a significant correlation between urine albumin levels and urine MMP-9 in DM subjects, and the higher the urine albumin level, the higher the urine MMP-9 levels.